Objective: To investigate the active ingredients and mechanism of Sophora alopecuroides L. in the treatment of alcoholic liver disease (ALD) based on network pharmacology and molecular docking techniques. Methods: The active ingredients in Sophora alopecuroides L. were screened by Herb platform, and the corresponding targets of active ingredients were searched in SIB database. The targets of alcoholic liver disease were obtained from NCBI and GeneCards databases. The mapping tool Venny 2.1 was used for intersection comparison to obtain common targets. The protein interaction analysis and visual presentation were performed on the String platform. The DAVID database was used for GO function and KEGG pathway enrichment analysis. Finally, AutoDock and PyMOL software were used for molecular docking. Results: Eight active ingredients and 97 effective targets were identified by network pharmacology. The mechanism of action might be related to cancer pathway, lipid and atherosclerosis, T cell receptor signaling pathway and VEGF signaling pathway, and the main targets involved were HSP90AA1, AKT1, FYN and AKT2. Molecular docking results showed that matrine, sophocarpine and sophoramine had good binding force with HSP90AA1, FYN and AKT1. Conclusion: Matrine, sophocarpine and sophoramine in Sophora alopecuroides L. can ameliorate ALD by inhibiting inflammatory response or apoptosis through multi-target and multi-pathway interactions.
[1] 杨冬晗, 张文龙, 侯瑞丽, 等. Toll样受体4信号途径在酒精性肝损伤中的作用研究进展[J]. 中国比较医学杂志, 2021, 31(10): 126-130.
[2] Ganesan M, Eikenberry A, Poluektova LY, et al. Role of alcohol in pathogenesis of hepatitis B virus infection[J]. World J Gastroenterol, 2020, 26(9): 883-903.
[3] 徐洪芹, 高沿航. 亚洲地区酒精性肝病的流行特征(2000年-2020年)[J]. 临床肝胆病杂志, 2022, 38(7): 1625.
[4] 李静静, 王福玲, 李嘉欣, 等. 基于网络药理学分析苦豆子生物碱抗肺癌的作用机制[J]. 特产研究, 2022, 44(5): 43-48.
[5] 尚博扬, 杨萍, 陈丽, 等. 苦豆子中生物碱成分的网络药理学研究[J]. 中国中药杂志, 2018, 43(1): 160-167.
[6] 邬国栋, 董佳妮, 谢华祎,等. 苦豆子总碱对小鼠急性酒精性肝损伤的保护作用[J]. 包头医学院学报,2021,37(7): 38-41.
[7] 陈静, 刘洋, 支文冰, 等. 苦豆子化学成分及其药理作用的研究进展[J]. 特产研究,2023, 45(1): 162-173, 179.
[8] 张田义, 赖新星, 李婷婷, 等. 基于网络药理学和分子对接技术探讨功劳叶、仙鹤草药对治疗缺血性中风的作用机制[J]. 中国药理学通报, 2021, 37(11): 1607-1613.
[9] 周艳彩, 孔晨帆, 杨佳潞, 等. 基于痰瘀毒病机探讨细胞焦亡与酒精性肝病的关系[J]. 中医药学报, 2022, 50(5): 1-4.
[10] 杨嘉懿, 崔宇. 诱导实验鸡骨草的干预作用与中药治疗ALD应用启示[J]. 世界科学技术-中医药现代化, 2021, 23(5): 1692-1697.
[11] Liu FZ, Li YB, Yang Y, et al. Study on mechanism of matrine in treatment of COVID-19 combined with liver injury by network pharmacology and molecular docking technology[J]. Drug Deliv, 2021, 28(1): 325-342.
[12] 朱晓燃. 清肝化瘀颗粒对原发性肝癌大鼠的治疗作用及主要成分对肝癌细胞增殖凋亡的影响[D]. 北京: 北京中医药大学, 2021.
[13] Zhang X, Xu H, Bi XY, et al. Src acts as the target of matrine to inhibit the proliferation of cancer cells by regulating phosphorylation signaling pathways[J]. Cell Death Dis, 2021,12(10): 931.
[14] 余淑霞, 吴璟, 杨卫东. 苦参碱对BALB/c免疫性肝损伤小鼠的保护作用[J]. 宁夏医科大学学报, 2009, 31(1): 11-12, 15.
[15] 孙孝凤, 王潇娅, 杨阳, 等. 槐果碱抗炎镇痛作用及机制的研究进展[J]. 医学综述, 2022, 28(8): 1515-1519.
[16] 张明发, 沈雅琴. 槐定碱的抗肿瘤药理作用研究进展[J]. 药物评价研究, 2021, 44(2): 452-460.
[17] 季宇彬, 赵贺, 王福玲. 槐果碱药理作用研究进展[J]. 中草药, 2018, 49(20): 4945-4948.
[18] Song CY, Shi J, Zeng X, et al. Sophocarpine alleviates hepatocyte steatosis through activating AMPK signaling pathway[J]. Toxicol In Vitro, 2013, 27(3): 1065-1071.
[19] 李素银, 王丽双, 游丽萍, 等. 槐果碱改善对乙酰氨基酚诱导的小鼠急性肝损伤机制研究[J]. 中药药理与临床, 2023, 39(8): 46-52.
[20] Jiang ZY, Meng Y, Bo L, et al. Sophocarpine attenuates LPS-induced liver injury and improves survival of mice through suppressing oxidative stress, inflammation, and apoptosis[J]. Mediators Inflamm, 2018, 2018: 5871431.
[21] 黄银秋, 周厚琴, 张璐, 等. 槐果碱对小鼠免疫性肝损伤保护作用的研究[J]. 中国医院用药评价与分析, 2017, 17(3): 297-299,303.
[22] Choudhury A, Bullock D, Lim A, et al. Inhibition of HSP90 and activation of HSF1 diminish macrophage NLRP3 inflammasome activity in alcohol-associated liver injury[J]. Alcohol Clin Exp Res, 2020, 44(6): 1300-1311.
[23] 李昂, 浦昕元, 姜语, 等. 酪氨酸激酶Fyn的生物学特性及其在肿瘤发生发展中的作用[J]. 中国细胞生物学学报, 2022,44(3): 451-459.
[24] 杜桂芳, 董金珂, 张婷, 等. Fyn与小鼠肝纤维化模型中胆汁酸代谢组分的相关性研究[J]. 传染病信息, 2018, 31(4): 326-330.
[25] Reyes-Gordillo K, Shah R, Arellanes-Robleedo J, et al. Akt1 and Akt2 isoforms play distinct roles in regulating the development of inflammation and fibrosis associated with alcoholic liver disease[J]. Cells, 2019, 8(11): 1337.
[26] Tang ZH, Lin BW, Li W, et al. Y-box binding protein 1 promotes chromatin accessibility to aggravate liver fibrosis[J]. Cell Signal, 2023, 109: 110750.
[27] Wei DQ, Tian X, Zhu LB, et al. USP14 governs CYP2E1 to promote nonalcoholic fatty liver disease through deubiquitination and stabilization of HSP90AA1[J]. Cell Death Dis, 2023, 14(8): 566.
[28] Ye Q, Liu Y, Zhang GJ, et al. Deficiency of gluconeogenic enzyme PCK1 promotes metabolic-associated fatty liver disease through PI3K/AKT/PDGF axis activation in male mice[J]. Nat Commun, 2023, 14(1): 1402.
